Literature DB >> 23391818

Transforming growth factor-β signaling in hepatocytes promotes hepatic fibrosis and carcinogenesis in mice with hepatocyte-specific deletion of TAK1.

Ling Yang1, Sayaka Inokuchi, Yoon Seok Roh, Jingyi Song, Rohit Loomba, Eek Joong Park, Ekihiro Seki.   

Abstract

BACKGROUND & AIMS: Transforming growth factor (TGF)-β-activated kinase 1 (TAK1) is activated in different cytokine signaling pathways. Deletion of Tak1 from hepatocytes results in spontaneous development of hepatocellular carcinoma (HCC), liver inflammation, and fibrosis. TGF-β activates TAK1 and Smad signaling, which regulate cell death, proliferation, and carcinogenesis. However, it is not clear whether TGF-β signaling in hepatocytes, via TGF-β receptor-2 (Tgfbr2), promotes HCC and liver fibrosis.
METHODS: We generated mice with hepatocyte-specific deletion of Tak1 (Tak1ΔHep), as well as Tak1/Tgfbr2DHep and Tak1/Smad4ΔHep mice. Tak1flox/flox, Tgfbr2ΔHep, and Smad4ΔHep mice were used as controls, respectively. We assessed development of liver injury, inflammation, fibrosis, and HCC. Primary hepatocytes isolated from these mice were used to assess TGF-β-mediated signaling.
RESULTS: Levels of TGF-β, TGF-βR2, and phospho-Smad2/3 were increased in HCCs from Tak1ΔHep mice, which developed liver fibrosis and inflammation by 1 month and HCC by 9 months. However, Tak1/Tgfbr2ΔHep mice did not have this phenotype, and their hepatocytes did not undergo spontaneous cell death or compensatory proliferation. Hepatocytes from Tak1ΔHep mice incubated with TGF-β did not activate p38, c-Jun N-terminal kinase, or nuclear factor-κB; conversely, TGF-β-mediated cell death and phosphorylation of Smad2/3 were increased, compared with control hepatocytes. Blocking the Smad pathway inhibited TGF-β-mediated death of Tak1-/- hepatocytes. Accordingly, disruption of Smad4 reduced the spontaneous liver injury, inflammation, fibrosis, and HCC that develops in Tak1ΔHep mice. Levels of the anti-apoptotic protein Bcl-xL, β-catenin, connective tissue growth factor, and vascular endothelial growth factor were increased in HCC from Tak1ΔHep mice, but not in HCCs from Tak1/Tgfbr2ΔHep mice. Injection of N-nitrosodiethylamine induced HCC formation in wild-type mice, but less in Tgfbr2ΔHep mice.
CONCLUSIONS: TGF-β promotes development of HCC in Tak1ΔHep mice by inducing hepatocyte apoptosis and compensatory proliferation during early phases of tumorigenesis, and inducing expression of anti-apoptotic, pro-oncogenic, and angiogenic factors during tumor progression.
Copyright © 2013 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23391818      PMCID: PMC3752402          DOI: 10.1053/j.gastro.2013.01.056

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  41 in total

1.  Expression of WISPs and of their novel alternative variants in human hepatocellular carcinoma cells.

Authors:  Melchiorre Cervello; Lydia Giannitrapani; Manuela Labbozzetta; Monica Notarbartolo; Natale D'Alessandro; Nadia Lampiasi; Antonina Azzolina; Giuseppe Montalto
Journal:  Ann N Y Acad Sci       Date:  2004-12       Impact factor: 5.691

Review 2.  Inhibition of TGFbeta signaling in cancer therapy.

Authors:  Carlos L Arteaga
Journal:  Curr Opin Genet Dev       Date:  2005-12-27       Impact factor: 5.578

3.  Heterozygous mice for the transforming growth factor-beta type II receptor gene have increased susceptibility to hepatocellular carcinogenesis.

Authors:  Y H Im; H T Kim; I Y Kim; V M Factor; K B Hahm; M Anzano; J J Jang; K Flanders; D C Haines; S S Thorgeirsson; A Sizeland; S J Kim
Journal:  Cancer Res       Date:  2001-09-15       Impact factor: 12.701

4.  Hepatocellular expression of a dominant-negative mutant TGF-beta type II receptor accelerates chemically induced hepatocarcinogenesis.

Authors:  S Kanzler; E Meyer; A W Lohse; P Schirmacher; J Henninger; P R Galle; M Blessing
Journal:  Oncogene       Date:  2001-08-16       Impact factor: 9.867

5.  Distortion of autocrine transforming growth factor beta signal accelerates malignant potential by enhancing cell growth as well as PAI-1 and VEGF production in human hepatocellular carcinoma cells.

Authors:  Yasushi Sugano; Koichi Matsuzaki; Yoshiya Tahashi; Fukiko Furukawa; Shigeo Mori; Hideo Yamagata; Katsunori Yoshida; Masanori Matsushita; Mikio Nishizawa; Junichi Fujisawa; Kyoichi Inoue
Journal:  Oncogene       Date:  2003-04-17       Impact factor: 9.867

6.  Autocrine stimulatory mechanism by transforming growth factor beta in human hepatocellular carcinoma.

Authors:  K Matsuzaki; M Date; F Furukawa; Y Tahashi; M Matsushita; K Sakitani; N Yamashiki; T Seki; H Saito; M Nishizawa; J Fujisawa; K Inoue
Journal:  Cancer Res       Date:  2000-03-01       Impact factor: 12.701

7.  IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis.

Authors:  Shin Maeda; Hideaki Kamata; Jun-Li Luo; Hyam Leffert; Michael Karin
Journal:  Cell       Date:  2005-07-01       Impact factor: 41.582

Review 8.  TGF-beta signaling in tumor suppression and cancer progression.

Authors:  R Derynck; R J Akhurst; A Balmain
Journal:  Nat Genet       Date:  2001-10       Impact factor: 38.330

9.  Transforming growth factor beta 1 stimulates vascular endothelial growth factor gene transcription in human cholangiocellular carcinoma cells.

Authors:  Christoph Benckert; Sven Jonas; Thorsten Cramer; Zofia Von Marschall; Georgia Schäfer; Michael Peters; Karola Wagner; Cornelia Radke; Bertram Wiedenmann; Peter Neuhaus; Michael Höcker; Stefan Rosewicz
Journal:  Cancer Res       Date:  2003-03-01       Impact factor: 12.701

10.  TGF-beta1-promoted epithelial-to-mesenchymal transformation and cell adhesion contribute to TGF-beta1-enhanced cell migration in SMMC-7721 cells.

Authors:  Zhen Xu; Min Xiong Shen; Dong Zhu Ma; Li Ying Wang; Xi Liang Zha
Journal:  Cell Res       Date:  2003-10       Impact factor: 25.617

View more
  59 in total

1.  TNFα in liver fibrosis.

Authors:  Yoon Mee Yang; Ekihiro Seki
Journal:  Curr Pathobiol Rep       Date:  2015-09-30

2.  Transforming growth factor beta signaling in hepatocytes participates in steatohepatitis through regulation of cell death and lipid metabolism in mice.

Authors:  Ling Yang; Yoon Seok Roh; Jingyi Song; Bi Zhang; Cheng Liu; Rohit Loomba; Ekihiro Seki
Journal:  Hepatology       Date:  2013-12-18       Impact factor: 17.425

3.  TAK1-mediated autophagy and fatty acid oxidation prevent hepatosteatosis and tumorigenesis.

Authors:  Sayaka Inokuchi-Shimizu; Eek Joong Park; Yoon Seok Roh; Ling Yang; Bi Zhang; Jingyi Song; Shuang Liang; Michael Pimienta; Koji Taniguchi; Xuefeng Wu; Kinji Asahina; William Lagakos; Mason R Mackey; Shizuo Akira; Mark H Ellisman; Dorothy D Sears; Jerrold M Olefsky; Michael Karin; David A Brenner; Ekihiro Seki
Journal:  J Clin Invest       Date:  2014-07-01       Impact factor: 14.808

Review 4.  Role of BMSCs in liver regeneration and metastasis after hepatectomy.

Authors:  Hua-Lian Hang; Qiang Xia
Journal:  World J Gastroenterol       Date:  2014-01-07       Impact factor: 5.742

5.  A novel role of hepatic epithelial transforming growth factor-β signaling in cholangiocarcinogenesis.

Authors:  Man Liu; Myth T S Mok; Alfred S L Cheng
Journal:  Ann Transl Med       Date:  2016-03

6.  TGFβ signaling: a friend or a foe to hepatic fibrosis and tumorigenesis.

Authors:  Dragana Kopanja; Pradip Raychaudhuri
Journal:  Ann Transl Med       Date:  2016-03

7.  NCOA5, IL-6, type 2 diabetes, and HCC: The deadly quartet.

Authors:  Debanjan Dhar; Ekihiro Seki; Michael Karin
Journal:  Cell Metab       Date:  2014-01-07       Impact factor: 27.287

Review 8.  TAK1 regulates hepatic cell survival and carcinogenesis.

Authors:  Yoon Seok Roh; Jingyi Song; Ekihiro Seki
Journal:  J Gastroenterol       Date:  2014-01-21       Impact factor: 7.527

9.  The deubiquitinating enzyme cylindromatosis mitigates nonalcoholic steatohepatitis.

Authors:  Yan-Xiao Ji; Zan Huang; Xia Yang; Xiaozhan Wang; Ling-Ping Zhao; Pi-Xiao Wang; Xiao-Jing Zhang; Michele Alves-Bezerra; Lin Cai; Peng Zhang; Yue-Xin Lu; Lan Bai; Mao-Mao Gao; Huan Zhao; Song Tian; Yong Wang; Zhi-Xiang Huang; Xue-Yong Zhu; Yan Zhang; Jun Gong; Zhi-Gang She; Feng Li; David E Cohen; Hongliang Li
Journal:  Nat Med       Date:  2018-01-01       Impact factor: 53.440

10.  Evaluating the antifibrotic potency of galunisertib in a human ex vivo model of liver fibrosis.

Authors:  Theerut Luangmonkong; Su Suriguga; Emilia Bigaeva; Miriam Boersema; Dorenda Oosterhuis; Koert P de Jong; Detlef Schuppan; Henricus A M Mutsaers; Peter Olinga
Journal:  Br J Pharmacol       Date:  2017-08-11       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.